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Abstract: The new 2019 European Society of Cardiology guidelines for the diagnosis and management of
chronic coronary syndromes emphasize the role of noninvasive functional imaging of myocardial ischemia
in diagnosing coronary artery disease to guide decision making regarding revascularization. Cardiac
magnetic resonance imaging (CMR) stands out relative to other imaging modalities given its high safety
profile, absence of ionizing radiation, and its versatility in encoding various image contrasts. It also allows
an assessment of myocardial function, ischemia, and viability as well as permits tissue characterization
including detection of edema in a single examination. In recent years, a number of meta‑analyses and
studies considering the role of CMR for detecting ischemia have been published. The recent multicenter
randomized MR‑INFORM trial has demonstrated the clinical utility of CMR in patients with stable
angina and cardiovascular risk factors. This landmark study has proved that a perfusion CMR‑based
strategy leads to a lower number of revascularizations while being noninferior to an invasive coronary
angiography with fractional flow reserve-guided therapy in terms of major adverse cardiac events at 1
year. In light of recent and future technical improvements, CMR will become increasingly important in
the assessment of myocardial ischemia in patients with chronic coronary syndromes.
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in a preclinical phase, before transforming into 
a stable symptomatic phase or an acute coronary 
syndrome, possibly leading to ischemic cardio‑
myopathy and heart failure.3,4
Cardiac magnetic resonance imaging (CMR) 
is a noninvasive imaging modality with high re‑
producibility, safety, and cost ‑effectiveness.5,6 
It is characterized by unparalleled versatility in 
terms of assessing cardiac function and mor‑
phology, for which CMR is the reference imaging 
method.7 CMR using late gadolinium enhance‑
ment (LGE ‑CMR) is the gold standard for de‑
tecting the presence and extent of infarct scar, 
being a strong predictor of clinical outcomes.3,8,9
The aim of our review was to comprehensive‑
ly summarize up ‑to ‑date knowledge of the diag‑
nostic utility of CMR for detecting myocardial 
Introduction Despite the tremendous im‑
provement in diagnostic and therapeutic options 
during the last decades, ischemic heart disease 
remains the leading cause of death worldwide, 
accounting for about 17% of all deaths and 10% 
of years of life lost according to the recent World 
Health Organization report.1 In Poland, ischemic 
heart disease is also accountable for the highest 
number of years of life lost by one person who 
died: each man who died from ischemic heart 
disease in 2014 lost on average 18 years of life, 
whereas each woman lost 11 years of life.2 Isch‑
emic heart disease is a chronic progressive dis‑
ease caused by coronary atherosclerosis, func‑
tional alterations of epicardial vessels, and/or 
impairment of microcirculation. All these condi‑
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preference, and local resources. A presence of de‑
terminants of the clinical likelihood of CAD, in‑
cluding cardiovascular risk factors, changes in 
resting ECG, LV dysfunction, abnormal exercise 
ECG, and coronary calcium assessable by com‑
puted tomography (CT) should be evaluated for 
a more accurate estimation of individual PTP.
The new guidelines allow the use of either 
coronary CT angiography (CCTA) or noninva‑
sive functional imaging of ischemia (by means 
of CMR, stress echocardiography, myocardial 
perfusion scintigraphy by single ‑photon emis‑
sion CT [SPECT] or positron emission tomogra‑
phy) as the initial diagnostic test. However, in 
the case of coronary stenosis detected by CCTA 
or invasive angiography, further noninvasive 
or invasive functional testing is recommended 
for revascularization decisions (with exclusion 
of >90% diameter stenosis detected during in‑
vasive angiography). Therefore, CCTA should be 
used mainly in patients with low PTP, without 
previous diagnosis of CAD, and when good im‑
age quality is expected. In young patients, tech‑
niques without radiation (ie, CMR, stress echo‑
cardiography) are preferred.4
Ischemia detection in chronic coronary 
syndromes According to the current 2018 
ESC / European Association for Cardio ‑Thoracic 
Surgery guidelines on myocardial revasculariza‑
tion, noninvasive functional imaging is recom‑
mended as the first ‑line approach in patients 
with CCS, regional wall motion abnormalities, 
or reduced LV ejection fraction (LVEF), who are 
considered suitable for subsequent coronary 
revascularization.4,12
Although conventional exercise stress test can 
reflect the real physical capacities of patients, 
it has numerous limitations. Due to low sensi‑
tivity and specificity in detecting obstructive 
CAD, it may be considered as an alternative di‑
agnostic test only when other methods are un‑
available.4 Superior diagnostic ability of stress 
imaging may distinguish patients who should 
ischemia in chronic coronary syndromes (CCS) 
and for guiding revascularization.
The ischemic cascade Angina pectoris and 
myocardial infarction occur late in patients suf‑
fering from coronary artery disease (CAD), being 
the last stage in the ischemic cascade. The first 
steps may be asymptomatic; therefore, sensitive 
diagnostic tests are needed. At the very begin‑
ning of the ischemic cascade, an imbalance be‑
tween oxygen supply and demand occurs, caus‑
ing a reduction of myocardial perfusion, fol‑
lowed by left ventricular (LV) diastolic dysfunc‑
tion and regional wall motion abnormalities. 
Later, electrical alteration develops that can be 
observed on electrocardiography (ECG). Finally, 
patients experience chest pain (FIGURE 1). The de‑
tection of myocardial perfusion defects is cru‑
cial for the early diagnosis of ischemia, because 
it appears earlier than diastolic and systolic dys‑
function assessed by echocardiography or ECG. 
Evaluation and prompt management of silent 
myocardial ischemia could prevent angina pec‑
toris and acute coronary syndrome in patients 
with CAD.7,10,11
Role of noninvasive diagnostic techniques 
in patients with suspected coronary ar‑
tery disease The  2019 European Society 
of Cardiology (ESC) guidelines for the diagno‑
sis and management of chronic coronary syn‑
dromes emphasize the importance of assessing 
the clinical likelihood of CAD to avoid unnec‑
essary diagnostic tests and possible false‑posi‑
tive results. Noninvasive diagnostics is recom‑
mended for patients, with a pretest probability 
(PTP) of more than 15%. Due to a newly defined 
PTP threshold and in the light of current clin‑
ical practice, the guidelines also allow to con‑
sider diagnostic testing in patients with lower 
PTP (5%–15%). However, the higher likelihood 
of a false ‑positive result must be taken into ac‑
count, and the individual decision should be 














 FIGURE 1 The ischemic cascade. Asterisks indicate the stages of ischemic cascade that are routinely assessed by cardiac magnetic resonance imaging.
 Abbreviations: ECG, electrocardiographic
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underwent index revascularization, whereas in 
the FFR group, 45% of patients underwent in‑
dex revascularization. Therefore, the use of per‑
fusion CMR was associated with a significantly 
lower number of invasive procedures.20,21
In the literature, there are also numerous 
meta ‑analyses of  stress perfusion CMR in 
comparison with other cardiac imaging meth‑
ods and invasive FFR, which have confirmed 
the high diagnostic accuracy of CMR on both 
a per ‑patient and per ‑vessel basis.22-26 Accord‑
ing to these meta ‑analyses, perfusion CMR 
has a sensitivity of 89% to 90% and specifici‑
ty of 85% to 94% on a per ‑patient basis, as well 
as a sensitivity of 87% to 91% and specificity 
of 85% to 91% on a per ‑vessel basis, when com‑
pared with the gold standard of invasive FFR 
measurements.22,25,26
Prognostic value of stress cardiac magnetic reso‑
nance imaging The importance of stress per‑
fusion CMR is not only due to its high diagnos‑
tic accuracy but also due to its ability to predict 
cardiac outcome and individual patient progno‑
sis.6,27-34 Jahnke et al28 have shown that patho‑
logical adenosine ‑stress CMR (defined as ≥1 seg‑
ment with an inducible perfusion deficit of >25% 
transmurality) or pathological dobutamine‑
‑stress CMR (≥1 segment with an inducible wall 
motion abnormality) identified patients at high 
risk for subsequent cardiac death or nonfatal 
myocardial infarction, whereas patients with 
normal stress CMR were at very low risk for car‑
diovascular events (3‑year event ‑free survival, 
84% vs 99%). Vincenti et al31 found that ischemia 
of at least 1.5 myocardial segments (equivalent 
to ~9% of the LV myocardium) in stress CMR was 
the strongest predictor of cardiac death, non‑
fatal acute myocardial infarction, and late cor‑
onary revascularization (>90 days after CMR). 
Patients without or with only one ischemic seg‑
ment had excellent outcomes and could thus be 
spared revascularization.
A meta ‑analysis of 19 studies (14 with vaso‑
dilator stress, 4 with dobutamine, and 1 using 
both), including 11 636 patients with a mean 
follow ‑up of 32 months, highlighted that a neg‑
ative stress CMR is associated with very low risk 
of cardiovascular death and acute myocardial in‑
farction and therefore has an excellent prognos‑
tic value in patients with known or suspected 
CAD. No significant difference between vasodila‑
tor and dobutamine ‑stress CMR was observed.30
Revascularization in chronic coronary syn‑
dromes According to current ESC guidelines, 
myocardial revascularization is recommended 
for patients with CCS when symptoms of angina 
persist despite optimal medical therapy, includ‑
ing antianginal drugs. It should also be consid‑
ered in patients with CAD and a large area of isch‑
emia documented in a functional noninvasive 
undergo revascularization to improve their 
prognosis from those who will not benefit from 
invasive management.4,12 The current ESC guide‑
lines do not favor any of the stress imaging tech‑
niques, but simply describe advantages and dis‑
advantages of each method.4,12
Stress cardiac magnetic resonance imaging 
and evidence ‑based medicine To confirm 
the role of CMR in the detection of cardiac isch‑
emia, a few large randomized clinical trials have 
been conducted. To date, there have been 3 ma‑
jor clinical trials (MR ‑IMPACT [Magnetic Reso‑
nance Imaging for Myocardial Perfusion Assess‑
ment in Coronary Artery Disease Trial],13 MR‑
‑IMPACT II,14,15 and CE ‑MARC [Clinical Evalua‑
tion of Magnetic Resonance Imaging in Coronary 
Heart Disease])16,17 comparing stress perfusion 
CMR imaging with SPECT. All 3 studies have 
shown noninferiority or superiority of CMR in 
the detection of ischemia. However, coronary 
X ‑ray angiography with only quantitative assess‑
ment of coronary stenosis was used as the ref‑
erence standard.13-17 In the multicenter prospec‑
tive CE ‑MARC 2 trial,18,19 1202 patients with 
suspected CAD (PTP, 10%–90%) were random‑
ized to adenosine ‑stress CMR–, SPECT‑, or Na‑
tional Institute for Health and Care Excellence 
guideline–based management. This study has 
shown that CMR and SPECT significantly re‑
duced the rates of unnecessary invasive coro‑
nary angiography (defined by a normal inva‑
sive fractional flow reserve [FFR >0.8 within 12 
months]).18,19 A detailed comparison of the most 
important prospective randomized clinical tri‑
als for perfusion CMR is presented in Supple‑
mentary material, Table S1.
In June 2019, the results from the landmark 
multicenter study MR ‑INFORM (MR Perfu‑
sion Imaging to Guide Management of Patients 
With Stable Coronary Artery Disease), compar‑
ing adenosine ‑stress CMR with FFR in patients 
with CAD, were published.20 A total of 918 pa‑
tients with stable typical angina symptoms and 
at least 2 cardiovascular risk factors or positive 
exercise treadmill test results were randomized 
to either a CMR‑ or invasive FFR–based strategy 
to guide coronary revascularization. Revascular‑
ization was performed when ischemia was ob‑
served for at least 6% of the myocardium or FFR 
was measured to be 0.8 or lower in the noninva‑
sive and invasive group, respectively. The MR‑
‑INFORM trial proved that adenosine ‑stress 
CMR is noninferior to invasive FFR in guiding 
coronary revascularization in patients with CCS. 
There was no difference in primary outcome de‑
fined by major adverse cardiac events (including 
all ‑cause mortality, nonfatal myocardial infarc‑
tion, and target ‑vessel revascularization) be‑
tween groups during the 12‑month follow ‑up. 
In the CMR group, only 48% of patients under‑
went coronary angiography and 36% of patients 
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To date, the most common method to assess per‑
fusion deficits is the visual evaluation performed 
by an experienced physician. However, semi‑
quantitative and quantitative methods may help 
objectify the study results in the near future. 
Semiquantitative analysis uses signal intensi‑
ty changes over time during first ‑pass perfu‑
sion for each myocardial segment, whereas ful‑
ly quantitative analysis is based on the calcu‑
lation of the total myocardial blood flow using 
pharmaco ‑physiological modelling.54-59
The great majority of clinical trials, including 
the recent MR ‑INFORM study, were performed 
on 1.5‑T scanners (Supplementary material, Ta-
ble S1), although 3.0‑T scanners may potential‑
ly offer advantages with regard to temporal and 
spatial resolution and resulting diagnostic accu‑
racy. The key problems of higher field strength 
are susceptibility artefacts, greater field inho‑
mogeneity, and higher local energy deposition, 
which might be a limitation for numerous mag‑
netic resonance imaging–conditional implants 
and devices.40,53,60-62
Dobutamine ‑stress cardiac magnetic resonance im‑
aging In contrast to first ‑pass perfusion imag‑
ing, where only differences in myocardial perfu‑
sion between the healthy and hypoperfused myo‑
cardium are visualized, dobutamine is an inotro‑
pic and chronotropic agent, which induces max‑
imal vasodilation and therefore leads to true 
ischemia and LV wall motion abnormalities in pa‑
tients with significant CAD. The protocol is sim‑
ilar to the one used in stress echocardiography 
with increasing doses of dobutamine and option‑
al addition of atropine until the target heart rate 
is reached: 85% of the maximal predicted heart 
rate = ([220 – age] × 0.85 bpm). During each stage 
lasting approximately 3 minutes, cine images are 
acquired in all 4 standard geometries (short ‑axis, 
2‑chamber, 3‑chamber, and 4‑chamber view; Sup‑
plementary material, Figure S2).
Inotropic stress is an alternative to vasodila‑
tor stress perfusion CMR in patients with severe‑
ly impaired renal function or other contraindica‑
tions to vasodilator medication or gadolinium‑
‑based CM.7,49,53,63,64 If there are no contraindica‑
tions to the use of CM, dobutamine ‑stress CMR 
can be combined with first ‑pass perfusion to in‑
crease sensitivity.65,66
In general, a sensitivity of 83% and a speci‑
ficity of 86% on a per ‑patient level for the de‑
tection of CAD defined by quantitative angiog‑
raphy (≥50% diameter stenosis) was reported.67
Assessment of infarct scar and viability 
of the myocardium The presence and sever‑
ity of perfusion deficits should always be inter‑
preted along with the presence and transmural‑
ity of infarct scars, because revascularization 
should be limited to those cases where the isch‑
emic myocardium has a potential to recover. 
test (ie, >10% of the LV myocardium), abnormal 
invasive FFR, coronary stenosis exceeding 90%, 
or LVEF of 35% or lower due to CAD (Supple‑
mentary material, Figure S1).4,12 However, despite 
these recommendations, there is currently no 
conclusive evidence supporting prognostic ben‑
efits from routine revascularization in patients 
with CCS, significant myocardial ischemia, or he‑
modynamically relevant coronary artery steno‑
sis; therefore, the best management is a subject 
of ongoing debate.4,12,35 For that reason, results 
from the ISCHEMIA trial (International Study 
of Comparative Health Effectiveness with Med‑
ical and Invasive Approaches), which investigates 
whether coronary revascularization, in addition 
to optimal medical therapy, improves prognosis 
in patients with CCS and moderate ‑to ‑severe 
myocardial ischemia assessed by noninvasive 
imaging, are highly anticipated in early 2020.36-38
Stress cardiac magnetic resonance imag‑
ing for the assessment of myocardial isch‑
emia Patients referred for CMR for assessing 
the presence and extent of ischemia undergo ei‑
ther perfusion CMR with a vasodilator (ie, ade‑
nosine, regadenoson, or dipyridamole) and gad‑
olinium contrast media (CM) or dobutamine‑
‑stress CMR with wall motion analysis. Admin‑
istration of CM gives the unique opportunity 
to combine the diagnosis of myocardial isch‑
emia with the determination of myocardial 
viability (LGE ‑CMR). Therefore, this compre‑
hensive technique is preferred in daily clinical 
practice. However, in the case of contraindica‑
tions to gadolinium ‑based CM, dobutamine‑
‑stress with assessment of inducible region‑
al wall motion abnormalities is recommended. 
A comprehensive comparison of medications 
(adenosine, regadenoson, dipyridamole, and 
dobutamine) available for stress CMR is pre‑
sented in TABLE 1.39-51
Vasodilator stress perfusion cardiac magnetic reso‑
nance imaging During perfusion CMR, the first‑
‑pass transit of a gadolinium ‑based CM through 
the LV myocardium is observed under hyperemia 
mediated by infusion of a vasodilator. In the 
healthy myocardium, the coronary microvascu‑
lature dilates during exercise and stress ensur‑
ing suitable tissue perfusion, whereas for signif‑
icantly stenosed coronary arteries, the distal mi‑
crovasculature is almost maximally dilated under 
rest conditions and hyperemia provoked by va‑
sodilators triggers a coronary steal effect. A CM 
used in CMR is a T1‑shortening agent; there‑
fore, the rapid passage of the CM bolus through 
the normally perfused LV myocardium appears 
bright in T1‑sensitive pulse sequences, whereas 
hypoperfused segments remain darker. Usually, 
3 short ‑axis slices are acquired every heartbeat, 
and the whole first ‑pass perfusion scan is per‑
formed during one breath ‑hold (FIGURE 2).7,40,49,52,53 
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inversely with the viability of the myocardi‑
um (FIGURE 3).69-71 It has been shown that infarct 
scars not exceeding 25% of the myocardial wall 
width are most likely to achieve functional re‑
covery after revascularization, whereas seg‑
ments with subendocardial hyperenhance‑
ment greater than 75% are unlikely to recov‑
er.70 A 50% transmurality of LGE has been pro‑
posed as the cutoff value to determine the via‑
ble myocardium that could potentially benefit 
from revascularization.71
As the gadolinium ‑based CM is not able to en‑
ter the intracellular space, it is distributed in 
the extracellular volume in the healthy myocar‑
dium but also in myocytes with ruptured cell 
membrane. Therefore, late gadolinium enhance‑
ment (LGE) is visible on T1‑weighted CMR im‑
ages as hyperenhancement in the necrotic myo‑
cardium. The subendocardial pattern of LGE al‑
lows to distinguish infarct scar from other myo‑
cardial fibrosis of nonischemic origin.7,49,53,68 
The transmurality of the infarct scar correlates 
TABLE 1 Comparison of cardiac magnetic resonance stress tests by pharmacological agents used (continued on the next page)
Criteria Adenosine Regadenoson Dipyridamole Dobutamine (+/- atropine)
Mechanism of action Perfusion CMR with a vasodilator induces flow heterogeneity between normal 
and ischemic myocardium





Selective low ‑affinity 
A2a specific adenosine 
receptor agonist (very 
weak agonist 
of the A1 adenosine 
receptor, negligible 
affinity to A2B and A3 
adenosine receptors)
Indirect drug acts by  





β ‑adrenergic agonist with 
inotropic and chronotropic 
effect (primarily β1‑adrenergic 
catecholamine with mild α1‑ 
and β2‑receptor agonist 
activity)
Patient preparation Withhold coffee, tea, chocolate, and aminophylline/theophylline for 12–24 
hours prior to CMR.
Withhold β ‑blockers, negatively 
chronotropic calcium 
antagonists, and nitrates for 
at least 24–48 hours prior to 
CMR (in order to achieve 
the target HR).
Contraindications General Severe claustrophobia (persistent after use of sedatives such as midazolam intranasal)
MRI ‑unsafe metallic implants, devices, defibrillators or permanent pacemakers (recommended source: 
www.mrisafety.com)
Specific Uncontrolled asthma 
or severe COPD
2nd‑ or 3rd ‑degree AV 
block, type II 2nd‑
‑degree AV block, 
sick sinus syndrome
Severe hypotension 










Recent use of digoxin /
verapamil
Uncontrolled asthma (active 
ongoing wheezing)
2nd‑ or 3rd ‑degree AV block, 
type II 2nd ‑degree AV 
block, sick sinus syndrome
Severe hypotension 




Asthma or tendency to 
bronchospasm
2nd‑ or 3rd ‑degree AV 
block, type II 2nd‑
‑degree AV block, sick 
sinus syndrome
Severe hypotension 
(SBP <90 mm Hg)
ACS <4 weeks
Recent unexplained 
syncope (within 4 
weeks) or with recent 
TIA
















Mobile thrombus in the left 
ventricle / left atrium / left 
atrial appendage
Atropine: narrow angle 
glaucoma, advanced prostate 
hypertrophy, myasthenia 
gravis, obstructive uropathy, 
obstructive gastrointestinal 
disorders
Half‑time Approx. 5–10 s
(onset of action after 
30 s)
Approx. 2–5 min
(initial phase: 2–4 min; 
intermediate phase: 
30 min, this phase 
coincides with a loss of the 
pharmacodynamic effect; 
terminal phase: 2 hours)
Approx. 30 min Approx. 2 min
Administration 2 IV cannulas (for 
separate 
administration 
of CM and 
vasodilator)
1 IV cannulas 2 IV cannulas 
(for separate 
administration of CM 
and vasodilator)
1 or 2 IV cannulas (1 if study 
without CM)
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TABLE 1 Comparison of cardiac magnetic resonance stress tests by pharmacological agents used (continued from the previous page)
Criteria Adenosine Regadenoson Dipyridamole Dobutamine (+/- atropine)
CMR 
protocol
Equipment ECG and BP monitoring system, CMR conditional monitoring system, defibrillator, resuscitation material, CMR 
conditional drug infusion pumps or placed outside of the room with long lines to feed into the scanner room
Agent dosage Adenosine infusion 
at 140 µg/min/kg 
for at least 3 min 
(when no response 
observed increase 
dose to 170 µg/min/
kg; if still not 
sufficient, 
210 µg/min/kg)
Regadenoson infusion bolus 
(0.4 mg in a rapid IV 
injection for approx. 10 s)
Dipyridamole infusion 
dose of 0.56 mg/kg 
for 4 min
If needed: 2nd dose 
of 0.28 mg/kg for 2 
min or 0.86 mg/kg for 
6 min
Dobutamine infusion at different 
doses in several stages: 10, 20, 
30, 40 µg/kg/min at 3–5 min 
per stage until 85% 
of the maximal predicted HR 
(0.85 × [220 – age]) is reached.
If the target HR is not achieved, 
doses of atropine may be added 
(0.5–2 mg IV).
Imaging Bolus injection of gadolinium CM (0.05–0.1 mmol/kg) and first ‑pass perfusion 
imaging (3 short ‑axis slices by every heartbeat)
Rest perfusion imaging after injection of a 2nd contrast dose (this study can be 
omitted in case of severe kidney disease), followed by LGE imaging
During each stage: cine images 
in 3 long ‑axis views and min. 
3 short ‑axis slices are acquired.
Evaluation of positive response Hemodynamic response (increase of heart rate >10 bpm or drop 
of SBP >10 mm Hg)
Symptoms (heat, difficulty breathing, tolerable chest pain, facial flushing)
Splenic switch off (only for adenosine)
Target HR








AV block (8%), 2nd‑





Dyspnea (29%), headache 
(27%), flushing (23%), 
chest pain (19%), 
gastrointestinal discomfort 
(15%), dizziness (11%)
Rhythm or conduction 
abnormalities (26%), 1st‑
degree AV block (3%), 2nd‑









Adverse reactions usually 




















Hypertension ≥220/120 mm Hg 
(0.5%)





Rupture of the free wall of the left 
ventricle or septal defect 
(extremely rare)
Indications to stop examination Hemodynamic and subjective positive response
Frequent / complex cardiac arrhythmias
Greater than transient AV block or severe bradycardia





Severe angina pectoris or 
dyspnea
Complex cardiac arrhythmias
Decrease in SBP ≥40 mm Hg with 
change in reported symptoms
Hypertension ≥240/120 mm Hg
New or worsening wall motion 
abnormalities in ≥1 segment
Patient request
Antidote Stop IV infusion
Aminophylline / 
theophylline





Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; AFl, atrial flutter; AMI, acute myocardial infarction; approx., approximately; AV, atrioventricular; 
BP, blood pressure; CM, contrast media; CMR, cardiac magnetic resonance imaging; COPD, chronic obstructive pulmonary disease; HR, heart rate; IV, intravenous; LGE, late 
gadolinium enhancement; MRI, magnetic resonance imaging; SBP, systolic blood pressure; TIA, transient ischemic attack; UA, unstable angina; VT, ventricular tachycardia; 
others, see FIGURE 1
not undergo revascularization, have poorer 
survival.7 3 It must be noted that the presence 
of infarct scar also predicts cardiovascular 
events in patients without a previous diagno‑
sis of CAD and without LV regional wall mo‑
tion abnormalities.7 2 ,76
It has been shown that infarct size and its 
transmurality assessed by LGE ‑CMR are bet‑
ter predictors of mortality and significant 
cardiac events than LVEF and LV volume.7 2-75 
Furthermore, patients with infarct scar pres‑
ent within the viable myocardium, who do 
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Standard CMR protocols for pharmacologi‑
cal stress and viability assessment are shown 
in Supplementary material, Table S2.
Future perspectives New techniques in CMR 
image reconstruction and automated quanti‑
tative analysis are developing rapidly and may 
become an alternative to a purely visual inter‑
pretation.56,58,7 7 Therefore, we would like to de‑
scribe some innovative approaches that in our 
opinion have the potential to become an impor‑
tant part of standard CMR evaluation of isch‑
emia in the next decade.
For precise differentiation of stress ‑induced 
myocardial ischemia and infarct scar, 3‑dimen‑
sionl (3D) image fusion of whole ‑heart dynamic 
CMR perfusion and LGE was proposed.78  Whole‑
‑heart dynamic CMR perfusion is based on a new 
3D acquisition sequences that allow readout 
of the entire examination volume at once in con‑
trast to routinely used 2D acquisition of separate 
slices.78-84
Hybrid imaging holds promise for the field 
of cardiac imaging and planning of myocardial 
revascularization. It may be of particular value 
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Mid‑ventricular Apical
 FIGURE 2 A 66‑year ‑old physically active male patient with atypical chest pain (pretest probability, 26%) with cardiovascular risk 
factors (arterial hypertension, dyslipidemia, type 2 diabetes mellitus, adiposity, former smoking) was referred for stress cardiac 
magnetic resonance imaging (CMR). A – the 3 slices of a standard CMR perfusion with adenosin. Stress ‑induced ischemia is seen 
in 4 segments (inferoseptal and inferior basal to mid ‑ventricular [dashed lines]). No myocardial hypoperfusion was observed 
during perfusion CMR at rest. In CMR with late gadolinium enhancement, no infarct scar and nonischemic pattern of myocardial 
fibrosis were detected. B – the patient was referred for coronary angiography, which revealed 50% stenosis in the distal circumflex 
artery (Cx; small vessel) and serial high ‑grade stenosis (60%–90%) in the right coronary artery, which was successfully treated with 
2 drug‑eluting stents.
 Abbreviations: LAD, left anterior descending coronary artery; PCI, percutaneous coronary intervention; RCA, right coronary artery





FIGURE 3 Graphical presentation of the association between myocardial viability and infarct scar transmurality (cardiac 
magnetic resonance imaging with late gadolinium enhancement, short ‑axis view)
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visualization of coronary stenosis and resulting 
stress perfusion deficits can help identify culprit le‑
sions. In recent years, there has been a considerable 
interest in the combination of SPECT and CCTA, 
but this combination of modalities has the disad‑
vantages of higher levels of ionizing radiation and 
suboptimal sensitivity of SPECT to detect CAD 
in comparison with stress perfusion CMR.13,85,86 
Therefore, a more promising option may be 3D fu‑
sion of CCTA and whole ‑heart dynamic 3D ‑CMR 
perfusion.87 The method was recently extended to 
also include information on CT ‑derived FFR and 
myocardial scar (FIGURE 4). A possible future solu‑
tion avoiding ionizing radiation is 3D fusion im‑
aging of 3D ‑CMR perfusion data with 3D ‑CMR 
coronary angiography performed within a single 
CMR examination.88
For patients with contraindications to vasodi‑
lator medication or gadolinium ‑based CM, it is 
important to provide alternative imaging tests 
for ischemia detection. One of the most prom‑
ising CMR methods is T1 mapping performed 
during vasodilator stress, which has shown to 
distinguish obstructive epicardial CAD from mi‑
crovascular dysfunction.89 The technique, how‑
ever, requires carefully designed imaging and 
processing protocols as effect sizes are relatively 
small. Changes in T1 can be related to the fact 
that the microcirculatory arteries in the isch‑
emic myocardium already dilate at rest and are 
not able to further respond to stress conditions. 
Therefore, due to the increased volume of myo‑
cardial blood, the T1 relaxation time is already 
prolonged at rest and does not change under 
stress conditions.89-91 
Another innovative noncontrast approach is 
the CMR blood oxygen level–dependent meth‑
od, which uses the paramagnetic features of de‑
oxyhemoglobin. An increased amount of this 
endogenous contrast agent results in signal re‑
duction on T2*‑weighted images and therefore 
indicates the myocardial oxygenation status 
during rest and vasodilator stress.92-94 A pre‑
liminary study showed that texture analysis 
of native CMR images may provide an alterna‑
tive to CM ‑dependent LGE ‑CMR in the diag‑
nosis of subacute and chronic infarction.95 Fi‑
nally, cardiac diffusion CMR allows an assess‑
ment of changes in myocardial extracellular 
volume and microstructure without the need 
for CM.96 -98
Another developing technique is hyperpo‑
larized carbon‑13 CMR, capable of visualizing 
the uptake of metabolic substrates and their 
FIGURE 4 Three ‑dimensional (3D) image fusion combining information from coronary computed tomography angiography 
(CCTA), computed tomography (CT)–derived fractional flow reserve (FFR), stress perfusion cardiac magnetic resonance imaging 
(CMR), and CMR with late gadolinium enhancement (LGE ‑CMR). Data from a 59‑year ‑old male patient with severe 3‑vessel 
coronary artery disease are shown. Conventional 2‑dimensional images of CT and CMR datasets (A – stress perfusion CMR; 
B – LGE ‑CMR) were postprocessed, coregistered, color ‑coded, and rendered in a 3D fashion. In CCTA, a subtotal proximal stenosis 
of the right coronary artery was found (C – 3D rendering, also note the associated drop of CT ‑derived FFR value), which resulted 
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intracellular transformation into downstream 
products. This metabolic CMR may potentially 
be involved also in evaluation of myocardial vi‑
ability and ischemia in the future.99,100
Conclusions As laid out in our review of 
the current literature, CMR plays a leading role 
in the diagnostic workup of patients with CCS. 
It allows an assessment of myocardial function, 
ischemia, and viability within a single nonin‑
vasive examination over a short period of time. 
Recent and future technical improvements will 
further increase its importance in the diagnostic 
assessment of myocardial ischemia and identi‑
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